AgriMetis Expands by Adding to Scientific Team
LUTHERVILLE, MD, March 1, 2018 – AgriMetis continues to expand its scientific capabilities and team by the addition of Dr. Anuradha Sundararajan as its Director of Fermentation and Strain Improvement.
Dr. Sundararajan has extensive industrial experience in improving microbial strains and fermentation processes. Prior to joining AgriMetis, she worked at Paragon Bioservices where she was involved with several client projects that included bacterial and yeast fermentation process development. She also worked at Igene Biotechnology in Maryland for 11 years as a Senior Scientist developing and improving strains of Phaffia/Xanthophyllomyces yeast for commercial production of carotenoids. Her experience at Igene also include Bacillus strain improvement, fermentation process development, scale up and technology transfer to manufacturing sites.
AgriMetis’ scientific approach of combining chemistry, biochemistry, and biology is multidisciplinary and integrated, which allows it to exploit areas of chemical space and production routes that are inaccessible to others. Dr. Brian Green, Vice President of Research and Development of AgriMetis, said, “We are very excited to have Anuradha join our team. She is well versed in all aspects of bacterial and yeast fermentation technology from strain improvement to product scale up and process development and optimization.”
Steve Tuttle, President and CEO of AgriMetis, added, “Anuradha’s proven expertise in improving and scaling up microbial fermentations will help AgriMetis drive its programs toward commercialization.”
Further information about AgriMetis and can be found at http://www.agrimetis.com.
In an evolving and growing global population, there continues to be an increasing demand for sustainable, crop protection products. AgriMetis is committed to working with leading agriculture companies and businesses to fill this emerging need.
Our mission is to innovate sustainable crop protection products through leading edge and advanced discovery, development and delivery methods.
The AgriMetis technology platform is at the interface of biology, biochemistry, and chemistry. AgriMetis’ scientific approach is multidisciplinary and integrated, which allows AgriMetis to exploit areas of chemical space and production routes that are inaccessible to others.
AgriMetis was formed in March 2014 and completed a Series B financing in December 2016 to fund agriculture chemical research and development by applying a biopharmaceutical model. With headquarters near Baltimore, Maryland, AgriMetis continues to grow and develop its technologies and capabilities.
For more information, please visit our website at http://www.agrimetis.com.
This press release contains “forward-looking statements” concerning the development of AgriMetis’ products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. AgriMetis undertakes no obligation to update any forward-looking statements for any reason.
Steven Tuttle, President & CEO
10751 Falls Road, Suite 300
Lutherville, MD 20193